secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-315196
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline
--------------------------------------------------------------------------------

- Richard Fair appointed President, CEO and board member, effective December 11, 2025.
- Co-founder Sam Kintz transitions to Head of Pipeline, remains at Enliven.
- Fair receives $660,000 base salary, 55% target bonus, and option award for 875,000 shares.
- Kintz receives $500,000 base salary, 55% bonus, and acceleration of 140,457 stock options.
- Company plans to initiate Phase 3 trial for ELVN-001 in CML in 2026, citing need for commercialization expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525315196/0001193125-25-315196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525315196/d937094d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-315196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer